Cargando…

Two cases of unresectable hepatocellular carcinoma treated via atezolizumab and bevacizumab combination therapy

BACKGROUND: Treatment of hepatocellular carcinoma (HCC) varies widely depending on the patient's condition. In recent years, combination therapy with immune checkpoint inhibitors has emerged as the treatment of choice due to its superior antitumor effects for unresectable HCC (uHCC). Conversion...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tsunemitsu, Ryosuke, Tabuchi, Motoyasu, Sakamoto, Shinya, Ogi, Kenta, Matsumoto, Manabu, Iwata, Jun, Okabayashi, Takehiro
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2023
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10236104/ https://www.ncbi.nlm.nih.gov/pubmed/37266831 http://dx.doi.org/10.1186/s40792-023-01678-9

Ejemplares similares

First case report of neoadjuvant gemcitabine and S-1 for locally advanced unresectable duodenal adenocarcinoma
por: Kimura, Jiro, et al.
Publicado: (2022)

A case of unresectable combined hepatocellular and cholangiocarcinoma treated with atezolizumab plus bevacizumab
por: Saito, Naoto, et al.
Publicado: (2022)

Corneal Perforation in a Patient Treated with Atezolizumab-Bevacizumab Combination Therapy for Unresectable Hepatocellular Carcinoma
por: Alkharashi, Majed S., et al.
Publicado: (2023)

Duodenojejunostomy for endoscopic management of biliary enteric anastomotic stricture inaccessible via balloon-assisted endoscopy: a case report
por: Sakamoto, Shinya, et al.
Publicado: (2023)

Epithelioid angiosarcoma of the duodenum: a case report
por: Sakamoto, Shinya, et al.
Publicado: (2022)

Atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma: Early clinical experience
por: Hiraoka, Atsushi, et al.
Publicado: (2021)

Atezolizumab plus bevacizumab versus sorafenib or atezolizumab alone for unresectable hepatocellular carcinoma: A systematic review
por: Ahmed, Faiza, et al.
Publicado: (2021)

Synchronous double primary malignancies of the pancreatic body and extrahepatic bile duct treated with pancreatoduodenectomy and splenic artery resection following neoadjuvant chemotherapy with gemcitabine plus nab-paclitaxel: a case report
por: Murokawa, Takahiro, et al.
Publicado: (2022)

Clinical Usefulness of Monitoring Muscle Volume during Atezolizumab Plus Bevacizumab Therapy in Patients with Unresectable Hepatocellular Carcinoma
por: Matsumoto, Hiroaki, et al.
Publicado: (2022)

Cost-utility analysis of atezolizumab with bevacizumab in untreated unresectable or advanced hepatocellular carcinoma in France
por: Gaugain, Loïg, et al.
Publicado: (2023)

Therapeutic Efficacy and Safety of Lenvatinib after Atezolizumab Plus Bevacizumab for Unresectable Hepatocellular Carcinoma
por: Yano, Shigeki, et al.
Publicado: (2023)

Adverse events as potential predictive factors of therapeutic activity in patients with unresectable hepatocellular carcinoma treated with atezolizumab plus bevacizumab
por: Tada, Toshifumi, et al.
Publicado: (2022)

Neutrophil-to-Lymphocyte and Platelet-to-Lymphocyte Ratios as Prognostic Biomarkers in Unresectable Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab
por: Wu, Yue Linda, et al.
Publicado: (2022)

Successful Lenvatinib Re-challenge following Atezolizumab Plus Bevacizumab Combination Therapy Failure for Unresectable Hepatocellular Carcinoma
por: Kosaka, Yumi, et al.
Publicado: (2022)

Hepatocellular carcinoma with gastric adenocarcinoma treated with atezolizumab and bevacizumab
por: Suga, Takayoshi, et al.
Publicado: (2023)

A Case of Pseudoprogression in Hepatocellular Carcinoma Treated With Atezolizumab Plus Bevacizumab
por: Watanabe, Yukinobu, et al.
Publicado: (2021)

Cost-effectiveness of Atezolizumab Plus Bevacizumab vs Sorafenib for Patients With Unresectable or Metastatic Hepatocellular Carcinoma
por: Zhang, Xin, et al.
Publicado: (2021)

Initial Experience of Atezolizumab Plus Bevacizumab for Unresectable Hepatocellular Carcinoma in Real-World Clinical Practice
por: Iwamoto, Hideki, et al.
Publicado: (2021)

The Prognostic Value of Baseline Clinical and Radiologic Imaging Features in Patients with Unresectable Hepatocellular Carcinoma Treated with Atezolizumab Plus Bevacizumab
por: Awiwi, Muhammad O, et al.
Publicado: (2022)

Changes in Serum Growth Factors during Resistance to Atezolizumab Plus Bevacizumab Treatment in Patients with Unresectable Hepatocellular Carcinoma
por: Yang, Zijian, et al.
Publicado: (2023)

Transarterial Chemoembolization Combined with Atezolizumab Plus Bevacizumab or Lenvatinib for Unresectable Hepatocellular Carcinoma: A Propensity Score Matched Study
por: Zhao, Chenghao, et al.
Publicado: (2023)

Immune Checkpoint Inhibitor-Related Pneumonia in Unresectable Hepatocellular Carcinoma: Two Fatal Cases under Atezolizumab plus Bevacizumab
por: Endo, Kei, et al.
Publicado: (2022)

Relationship of Atezolizumab plus Bevacizumab Treatment with Muscle Volume Loss in Unresectable Hepatocellular Carcinoma Patients: Multicenter Analysis
por: Hiraoka, Atsushi, et al.
Publicado: (2022)

Cost-effectiveness of Atezolizumab Plus Bevacizumab vs Sorafenib as First-Line Treatment of Unresectable Hepatocellular Carcinoma
por: Su, Dan, et al.
Publicado: (2021)

High serum IL-6 correlates with reduced clinical benefit of atezolizumab and bevacizumab in unresectable hepatocellular carcinoma
por: Yang, Hannah, et al.
Publicado: (2023)

Effectiveness and safety of atezolizumab-bevacizumab in patients with unresectable hepatocellular carcinoma: a systematic review and meta-analysis
por: Kulkarni, Anand V., et al.
Publicado: (2023)

Risk Factors for Early Onset of Proteinuria in Patients Receiving Atezolizumab Plus Bevacizumab for Unresectable Hepatocellular Carcinoma
por: Ando, Yuwa, et al.
Publicado: (2022)

Case Report: Atezolizumab plus bevacizumab for combined hepatocellular-cholangiocarcinoma
por: Satake, Tomoyuki, et al.
Publicado: (2023)

Atezolizumab plus bevacizumab combination enables an unresectable hepatocellular carcinoma resectable and links immune exclusion and tumor dedifferentiation to acquired resistance
por: Wang, Yulei, et al.
Publicado: (2021)

Exophytic pancreatic lymphoepithelial cyst incidentally detected in a differentiated thyroid cancer patient on whole-body I-131 scan: a case report
por: Murokawa, Takahiro, et al.
Publicado: (2022)

Fibrolamellar hepatocellular carcinoma treated with atezolizumab and bevacizumab: two case reports
por: AL Zahrani, Ali, et al.
Publicado: (2021)

Early Tumor Response and Safety of Atezolizumab Plus Bevacizumab for Patients with Unresectable Hepatocellular Carcinoma in Real-World Practice
por: Ando, Yuwa, et al.
Publicado: (2021)

Initial therapeutic results of atezolizumab plus bevacizumab for unresectable advanced hepatocellular carcinoma and the importance of hepatic functional reserve
por: Tomonari, Tetsu, et al.
Publicado: (2022)

Atezolizumab plus bevacizumab-induced intratumoral hemorrhage in a patient with rib metastasis from unresectable hepatocellular carcinoma
por: Mitsuyama, Yasuhito, et al.
Publicado: (2023)

Factors associated with the response to atezolizumab/bevacizumab combination therapy for hepatocellular carcinoma
por: Yano, Yoshihiko, et al.
Publicado: (2023)

Comparison of Efficacy and Safety of Atezolizumab Plus Bevacizumab and Lenvatinib as First-Line Therapy for Unresectable Hepatocellular Carcinoma: A Propensity Score Matching Analysis
por: Niizeki, Takashi, et al.
Publicado: (2022)

Duodenal Variceal Rupture during Atezolizumab and Bevacizumab Treatment for Hepatocellular Carcinoma
por: Tsuruoka, Mio, et al.
Publicado: (2022)

Atezolizumab plus bevacizumab versus sorafenib as first‐line treatment for unresectable hepatocellular carcinoma: a cost‐effectiveness analysis
por: Hou, Yanli, et al.
Publicado: (2020)

Similar efficacy and safety between lenvatinib versus atezolizumab plus bevacizumab as the first‐line treatment for unresectable hepatocellular carcinoma
por: Su, Chung‐Wei, et al.
Publicado: (2022)

Atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma progressing after molecular targeted therapy: A multicenter prospective observational study
por: Sugimoto, Rie, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_btq3nbinh1qn49kbbhutaspgd0